NEO Q1 Earnings Call: Sales Growth, Pharma Headwinds, and Pathline Integration Shape Outlook
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell short of the market's revenue expectations in Q1 CY2025, but sales rose 7.5% year on year to $168 million. On the other hand, the company's full-year revenue guidance of $753 million at the midpoint came in 2% above analysts' estimates. Its non-GAAP loss of $0 per share was in line with analysts' consensus estimates.
Is now the time to buy NEO? Find out in our full research report (it's free).
Revenue: $168 million vs analyst estimates of $170.9 million (7.5% year-on-year growth, 1.7% miss)
Adjusted EPS: $0 vs analyst estimates of -$0.01 (in line)
Adjusted EBITDA: $7.07 million vs analyst estimates of $5.27 million (4.2% margin, 34.3% beat)
The company lifted its revenue guidance for the full year to $753 million at the midpoint from $740 million, a 1.8% increase
EBITDA guidance for the full year is $56.5 million at the midpoint, above analyst estimates of $55.63 million
Operating Margin: -16.6%, up from -19.6% in the same quarter last year
Free Cash Flow was -$29.83 million compared to -$31.5 million in the same quarter last year
Market Capitalization: $1.1 billion
NeoGenomics' first quarter results reflected continued growth in clinical testing, particularly from its next-generation sequencing (NGS) portfolio and expanded commercial reach. Management attributed the increase in clinical test volumes and revenue per test to the successful launch of five new NGS products and targeted investments in its salesforce, as well as the recent acquisition of Pathline, which expands the company's Northeast presence. CEO Tony Zook emphasized that the company's strategy remains focused on serving community oncology providers, with new product launches and operational efficiencies supporting ongoing momentum.
Looking ahead, leadership lifted full-year revenue guidance, underpinned by the expected benefits from Pathline, additional NGS product introductions, and commercial partnerships such as the collaboration with Adaptive for minimal residual disease (MRD) testing. Management also cautioned that macroeconomic pressures, including weaker pharma and biotech spending and non-clinical revenue headwinds, are likely to persist but will be offset by growth in the core clinical business. CFO Jeff Sherman reiterated NeoGenomics' commitment to financial discipline, stating, 'We will continue to take a balanced approach to investments with increasing adjusted EBITDA, enabling further investments to drive operating efficiencies in the business and targeted investments in R&D.'
NeoGenomics' management highlighted several major factors shaping first quarter performance, with accelerating growth in clinical diagnostics and ongoing investment in new products and operational capabilities.
NGS Segment Drives Growth: The launch of five new next-generation sequencing (NGS) tests accounted for 22% of total clinical revenue, reflecting strong adoption within community oncology practices. Management noted that deeper relationships with community hospitals are providing a competitive edge and driving higher-value test utilization.
Pathline Acquisition Expands Market Reach: The recently closed acquisition of Pathline, a New York state-approved laboratory, establishes a physical presence in the Northeast and is expected to accelerate top-line growth by improving access to regional providers. Integration efforts are underway, with management expecting incremental clinical revenue contributions this year and greater earnings impact in 2026.
Salesforce Expansion to Support Penetration: NeoGenomics completed the expansion of its commercial team to approximately 140 salespeople, aiming for near one-to-one coverage between hospital pathology and community oncology. Leadership sees this as critical to supporting upcoming product launches and deepening market penetration.
Non-Clinical Revenue Pressure: The pharma and biotech segment, which comprises about 10% of total revenues, remains under pressure due to reduced research spending and macroeconomic factors such as tariffs and potential NIH funding cuts. Management acknowledged this headwind but maintained confidence in the long-term strategic value of the segment.
Product Pipeline Highlights: Validation and early-access programs for PanTracer liquid biopsy, an NGS-based blood test, have generated strong interest from community oncologists. The company also highlighted a new partnership with Ultima Genomics for low-cost, high-quality sequencing and ongoing development of next-generation MRD technologies, aiming for product launches in the next two years.
Management's outlook for the remainder of the year is anchored by the continued expansion of NGS offerings, Pathline integration, and the maturing salesforce, while acknowledging ongoing challenges in the non-clinical segment and industry-wide macro pressures.
NGS and Product Launches: Future growth is expected to come from the commercial launch of PanTracer liquid biopsy and upgrades to the comprehensive NGS panel, along with increased adoption of MRD testing through the Adaptive partnership. Leadership anticipates these launches will drive higher test volumes and revenue per test.
Pathline Integration Synergies: Successful integration of Pathline is expected to gradually enhance operating leverage and support incremental clinical revenue, with more substantial benefits projected for 2026 as NeoGenomics' full test menu becomes available to Pathline's customer base.
Non-Clinical Revenue Headwinds: Management warned that continued softness in pharma and biotech spending, along with external factors such as tariffs and research funding uncertainty, could further weigh on non-clinical revenues in the near-term. The company expects core clinical growth to offset these headwinds but highlighted this as a key risk.
Andrew Brackman (William Blair): Asked CEO Tony Zook about any early surprises since taking the helm and whether any business areas need more attention; Zook replied he saw no major surprises and reaffirmed confidence in the company's trajectory.
Dan Brennan (TD Cowen): Requested details on full-year pharma headwinds and Pathline's contribution to Q2 guidance; CFO Jeff Sherman clarified pharma revenue is expected to decline, with Pathline adding $3–$4 million per quarter and ramping up in later quarters.
Tejas Savant (Morgan Stanley): Inquired about capital deployment after paying down convertible notes, and the flexibility to invest in new product launches; Sherman stated cash flow will improve in 2026, providing options for the next round of debt.
Matthew Sykes (Goldman Sachs): Probed the outlook for average revenue per test (AUP) amid Pathline integration; Sherman explained Pathline's lower AUP will dilute the blended metric, but core modalities are still seeing incremental gains.
David Westenberg (Piper Sandler): Asked about the salesforce ramp and when new hires reach full productivity; Warren Stone said most additions are complete, with expected full productivity reached in six to nine months, pointing to late 2025 and early 2026 for maximum impact.
In the coming quarters, the StockStory team will be watching (1) the commercial launch and physician adoption of PanTracer liquid biopsy and related NGS upgrades, (2) the pace and success of Pathline integration, including the rollout of NeoGenomics' test menu to new customers, and (3) progress on operating efficiencies and cost-saving initiatives as the expanded salesforce matures. Execution on partnerships, especially with Adaptive and Ultima Genomics, and visibility into non-clinical revenue stabilization will also be important indicators of strategic execution.
NeoGenomics currently trades at a forward P/E ratio of 38×. Should you double down or take your chips? See for yourself in our free research report.
Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.
While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Private companies who hold 57% of Newegg Commerce, Inc. (NASDAQ:NEGG) gained 118%, insiders profited as well
Newegg Commerce's significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public Hangzhou Lianluo Interactive Information Technology Co.,Ltd owns 57% of the company 31% of Newegg Commerce is held by insiders AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. A look at the shareholders of Newegg Commerce, Inc. (NASDAQ:NEGG) can tell us which group is most powerful. And the group that holds the biggest piece of the pie are private companies with 57% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Private companies gained the most after market cap touched US$101m last week, while insiders who own 31% also benefitted. Let's take a closer look to see what the different types of shareholders can tell us about Newegg Commerce. See our latest analysis for Newegg Commerce Small companies that are not very actively traded often lack institutional investors, but it's less common to see large companies without them. There are many reasons why a company might not have any institutions on the share registry. It may be hard for institutions to buy large amounts of shares, if liquidity (the amount of shares traded each day) is low. If the company has not needed to raise capital, institutions might lack the opportunity to build a position. It is also possible that fund managers don't own the stock because they aren't convinced it will perform well. Newegg Commerce's earnings and revenue track record (below) may not be compelling to institutional investors -- or they simply might not have looked at the business closely. We note that hedge funds don't have a meaningful investment in Newegg Commerce. Our data shows that Hangzhou Lianluo Interactive Information Technology Co.,Ltd is the largest shareholder with 57% of shares outstanding. With such a huge stake in the ownership, we infer that they have significant control of the future of the company. Meanwhile, the second and third largest shareholders, hold 31% and 0.2%, of the shares outstanding, respectively. Faching Chang, who is the second-largest shareholder, also happens to hold the title of Top Key Executive. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Our information suggests that there isn't any analyst coverage of the stock, so it is probably little known. While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO. Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances. Our information suggests that insiders maintain a significant holding in Newegg Commerce, Inc.. Insiders have a US$31m stake in this US$101m business. We would say this shows alignment with shareholders, but it is worth noting that the company is still quite small; some insiders may have founded the business. You can click here to see if those insiders have been buying or selling. With a 11% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Newegg Commerce. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies. We can see that Private Companies own 57%, of the shares on issue. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company. I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Case in point: We've spotted 2 warning signs for Newegg Commerce you should be aware of. Of course this may not be the best stock to buy. So take a peek at this free free list of interesting companies. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
33 minutes ago
- Yahoo
Establishment Labs Hosting Investor Day on June 12
NEW YORK, June 11, 2025--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, will host its previously announced analyst and investor event in New York City on June 12, 2025 beginning at 1pm ET. A live and archived webcast of presentations and Q&A sessions on June 12 will be available on the "Investors" section of the Establishment Labs website at In-person attendance at the event is limited and requires advanced registration. Please email: ir@ for further information. About Establishment Labs Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women's health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The Company offers a portfolio of solutions for breast health, breast aesthetics, and breast reconstruction in over 90 countries. With over four million Motiva ® devices delivered to plastic and reconstructive surgeons since 2010, the Company's products have created a new standard for safety and patient satisfaction. The company's minimally invasive platform consists of Mia Femtech®, a unique minimally invasive experience for breast harmonization, and Preservé™, a breast tissue preserving and minimally invasive technology for breast augmentation, revision augmentation and mastopexy augmentation. GEM® is a next generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB approved pivotal study. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Zensor™ is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company's first biosensor Zen°™, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by over 200 patent applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2024 and FDA 21 CFR 820. Please visit our website for additional information at View source version on Contacts Investor/Media Contact: Raj Denhoy415 828-1044rdenhoy@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
38 minutes ago
- Business Wire
Establishment Labs Hosting Investor Day on June 12
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, will host its previously announced analyst and investor event in New York City on June 12, 2025 beginning at 1pm ET. A live and archived webcast of presentations and Q&A sessions on June 12 will be available on the "Investors" section of the Establishment Labs website at In-person attendance at the event is limited and requires advanced registration. Please email: ir@ for further information. About Establishment Labs Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women's health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The Company offers a portfolio of solutions for breast health, breast aesthetics, and breast reconstruction in over 90 countries. With over four million Motiva ® devices delivered to plastic and reconstructive surgeons since 2010, the Company's products have created a new standard for safety and patient satisfaction. The company's minimally invasive platform consists of Mia Femtech®, a unique minimally invasive experience for breast harmonization, and Preservé™, a breast tissue preserving and minimally invasive technology for breast augmentation, revision augmentation and mastopexy augmentation. GEM® is a next generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB approved pivotal study. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Zensor™ is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company's first biosensor Zen°™, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by over 200 patent applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2024 and FDA 21 CFR 820. Please visit our website for additional information at
